Gene Vector Market - By Vector (Plasmid DNA, Adeno-Associated Viral, Retroviral), By Application (Gene Therapy, Vaccinology), By Disease (Oncology, Genetic, Infectious) By End-user (CDMO, CRO, Pharma & Biotech Companies), Global Forecast 2023-2032

Gene Vector Market Size

Gene Vector Market size was valued at more than USD 1.20 billion in 2022 and will progress tremendously to reach over USD 4.11 billion by 2032 at 13.1% CAGR. Increase in prevalence of genetic disorders, development of more advanced gene editing technologies, and increasing demand for personalized medicine will drive the market growth.
 

In October 2021, as per the report published by the Genetic and Rare Diseases (GARD) Information Center, more than 30 million people in the United States are thought to be affected by one of the more than 7,000 rare diseases that exist. Cells and genetically modified cells are "living drugs" that repair and replace damaged tissues or ill organs, which makes them fundamentally different from medications and surgery. Due to these characteristics, they are used to treat a variety of conditions.
 

A gene vector, as related to molecular biology, is a DNA molecule (often plasmid or virus) that is used as a vehicle to carry a particular DNA segment into a host cell as part of a cloning or recombinant DNA technique. Gene vectors can be applied in gene therapy to treat different diseases such as cancer, metabolic diseases, heart defects, infectious diseases, and neurodegenerative disorders.
 

Covid-19 Impact

The COVID-19 outbreak is positively impacted the gene vector market. Several COVID-19 vaccine candidates entered clinical trials also include gene vector vaccines. These vaccines are likely to be among the COVID-19 vaccines authorized for use worldwide. Many of them have also received or are in the final stages of receiving approval. In January 2021, Johnson & Johnson announced favourable efficacy and safety data from its Phase 3 ENSEMBLE clinical trial using its AdVac adenoviral vector vaccine platform for COVID-19. Its single-dose COVID-19 vaccine. In addition to mRNA vaccines, the most advanced technology for COVID-19 vaccines is Ad vectors.
 

Adenoviruses are most utilized and advanced viral gene vectors developed for SARS-CoV-2 vaccines. They are non-enveloped double-stranded DNA (dsDNA) viruses with a packaging capacity of up to 7.5 kb of foreign genes. The AdVac viral vector technology could provide a potent and long-lasting humoral and cellular immune response to the body.
 

The COVID-19 viral vector vaccines are developed worldwide using non-replicating gene vectors. The immune response of these vaccines follows a similar pattern, i.e., it includes antibody-producing B cells and T cells, which seek out and destroy infected cells in the body, providing long-lasting immunity. Further research and increased investment in this field are expected to positively affect vaccine development.
 

Gene Vector Market Trends

Gene vector industry revenue growth is driven by factors such as rising prevalence of genetic disorders, cancer, and infectious diseases, development of more advanced gene editing technologies, and increasing demand for personalized medicine. Gene vectors are necessary for the delivery of gene treatments into target cells in many instances of gene therapy, with viral vectors being among the most extensively studied vectors owing to their unique benefits, such as their exceptional transduction efficiency.
 

Various products using viral vectors to deliver therapeutic genes have been approved for use against cancer, infectious diseases, and monogenic disorders. Also, several clinical tests are currently being conducted to increase their therapeutic utility. Gene delivery methods rely on retrovirus, Adenovirus (Ad), poxvirus, Herpes Simplex Virus (HSV), and Adeno-Associated Virus (AAV) has been employed in over 66% of all gene therapy clinical trials to date. These viruses were initially used to build gene delivery systems because they are easily controlled in vitro and have been extensively investigated. Numerous characteristics of these viral vectors affect their potential for various therapeutic applications.
 

Gene Vector Market Analysis

Based on vector type, the gene vector market is segmented into plasmid DNA, retroviral, lentiviral, adenoviral, adeno-associated viral, and other vectors. The plasmid DNA held largest market share in 2022 and the trend is likely to remain so over the forecast period. There is also an increase in several genetic disorders and numerous life-threatening disorders, especially heart diseases, AIDS, cystic fibrosis, and age-related disorders. Gene therapy with gene vectors provides a complete cure to patients suffering from genetic disorders and other life-threatening disorders rather than ease symptoms with other treatments.
 

Based on application, the gene vector market is segmented into gene therapy, vaccinology, and other applications. The gene therapy accounted for the largest market share in overall market in 2022. This is attributed to the fact that gene therapy is widely used in the treatment for various genetic disorders and inherited disorders. Moreover, continuous technological advancements in developing reliable and safe treatment for different diseases is boosting the growth of this segment.
 

Gene therapy is the advanced treatment applied for cancer, chronic disease, infectious disease, and blood disorders. Gene therapy involves the partial or full replacement of defective genes in a patient's body with healthy ones to treat or prevent disease proliferation.
 

By diseases, the gene vector market is segmented into oncology, genetic disorders, infectious disease, and other diseases. The oncology segment was the largest revenue generating segment in the market in 2022. The upsurge in the global incidence of cancer and modern healthcare facilities are acting as major drivers for the segment growth. According to GLOBOCAN 2020, there were 1,92,92,789 new cancer cases in 2020, and it is projected to increase to 2,88,87,940 cases by 2040. Additionally, there are also many gene therapy strategies that have been developed to treat a wide range of cancers, including suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines.
 

By end user, the gene vector market is segmented into research institutes, CROs, CDMOs, and other end users. The CDMOs segment held the larger market share in 2022. CDMOs engaged in gene and cell therapy research are anticipated to see a growth in demand for gene vectors due to rising investments for the development of gene therapy. organization. In addition, research organizations, CROs, pharmaceutical, and biopharmaceutical companies are the key end users in the gene vectors market, contributing to an increase in the introduction of sophisticated medicines and a growing number of gene therapy-based R&D initiatives.
 

North America dominated the gene vector market with a share of 53.8% in 2022. Some of the major factors that have contributed to the large share of this regional market are the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced gene therapies. Investments made by the federal bodies for the expansion of cell therapy research base in the region are anticipated to enhance the growth of North America market.
 

Gene Vector Market Share

The Key gene vector market players include :

• Cobra Biologics
• Fujifilm Diosynth Biotechnologies
• SIRION Biotech
• Merck KGaA Inc.
• Thermo Fisher Scientific.
• Lonza
• Oxford Biomedica
• Novasep
• Spark Therapeutics
• Kaneka Eurogentec
• Finvector Vision Therapies,
• Brammer Bio

Moreover, various strategies, such as research and development investments, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position. For instance, In July 2021, the company Thermo Fisher Scientific Inc. announced the launch of new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif which will fulfil the growing demand of plasmid DNA-based therapies and viral mRNA-based vaccines.
 

Gene vector market industry news:

• In November 2022, Thermo Fisher Scientific, introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. it is the only product of its kind that is manufactured under cGMP conditions to enable large-scale application.
   
• In October 2022, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition industries, announced two additional cell and gene therapies manufactured at its Houston (US) site have reached commercial approval in Q3 2022. ZYNTEGLO.
   

The gene vector market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Vector Type

• Plasmid DNA
• Adenoviral
• Adeno-associated viral
• Retroviral
• Lentiviral
• Other vector types

By Application

• Gene therapy
• Vaccinology
• Other applications

By Diseases

• Oncology
• Genetic disorders
• Infectious diseases
• Other diseases 

By End-Use

• CDMOs
• Pharmaceutical and biotechnology companies
• Research institutes  
• CROs

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe          
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia & The Newzealand
  • Rest of Asia Pacific   
• Latin America       
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa        
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa